A German-style fair value/pricing committee may be in the works for the United States. However, government payers still have work to do before implementing a value assessment system. The adoption of a ...

Much of the biopharmaceutical industry this week is focused on the J.P. Morgan Healthcare Conference (JPM), where business leaders are investing in science and technologies with the potential to ...

This post is part of the Health Affairs Forefront short series, “Value Assessment: Where Do We Go Post-COVID?” The series explores what we have learned about value assessment and related issues during ...

There are shortcomings in the ways we have approached value assessment to date, writes the executive director of the Innovation and Value Initiative. Jennifer Bright is the executive director of the ...